The role of IL-2 in expanding tumor-infiltrating lymphocytes and supporting durable responses is well documented, with high-dose IL-2 therapy historically approved for metastatic melanoma and associated with improved outcomes in selected patients [36,44]. The gene discussed is IL2; the disease is metastatic melanoma.